Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon’s acquisition of Arana Therapeutics ‘complete’

Cephalon’s acquisition of Arana Therapeutics ‘complete’

11th August 2009

Cephalon has announced that its acquisition of Australian biotechnology firm Arana Therapeutics has been carried out successfully.

The transaction will result in the expansions of Cepahlon’s technology portfolio and will form the basis of the firm’s biologics arm.

According to the chairman and chief executive officer of Cephalon Frank Baldino, the company is enthusiastic about the “advanced biological and molecular technology expertise” Arana can bring to the table.

“With biologics in inflammatory diseases and clinical candidates in oncology for solid tumors, this acquisition will catalyse the entry of Cephalon into the biologics space,” Mr Baldino continued.

Established in 1987, Cephalon employs around 3,000 people in the US and Europe and also has a growing presence in the Middle East and Africa.

It acquires protein engineering technologies in order to transform proteins into drug candidates and has successfully developed ART621, which targets TNF alpha, among several other products.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.